David Evans is chairman and entrepreneurial investor in a number of companies with a demonstrable track record in both taking companies through the IPO process ( as Chairman) and delivering value to shareholders in the public phase of a company. Past Finance Director and CEO of Axis Shield and Chairman of DxS, BBI Group and Immunodiagnostics. Current Chairman of Epistem, EKF Diagnostics & Scancell. A substantial track record

Dr Blair is also Managing Director of Integrated Medicines Ltd (IML), non-executive director (Rem Com Chair) of Immunodiagnostic Holdings PLC, and visiting scholar at Cambridge University. He is named inventor on many patents, including one on magnetic proteins, the technology being exploited by IMSL. Since leaving GlaxoSmithKline in 2003 (global director of clinical diagnostics) he has raised >£10M equity finance to support AIM IPOs.

Dr Dehal invented the magnetic protein technology while at Axis‐Shield Diagnostics plc, where she was a principle scientist. She is a molecular immunologist specialising in the application of antibodies for immunodiagnostics and trained at the Paterson Institute and the University of Dundee in making recombinant antibodies and sub-fragments.

Michael Martin is an investment banker with over thirty years experience advising on Private Equity, Mergers & Acquisitions, and IPOs in Europe, USA and Asia. A founding partner of an independent corporate finance firm (Anvil Partners), he has spent the past fifteen years advising entrepreneurially led businesses on raising private equity funds and exits, and invests personally in many of these businesses.